Al's Comment:

 Very exciting news. This is a new approach which targets CD29 which controls a tumors' growth, invasiveness and resistance.  I wish this patient well (as well as future patients in the trial!). The Musella Foundation played a small part in the development of this drug by giving research grants to them!


Posted on: 03/10/2021

OncoSynergy Announces First Patient Treated in First-in-Human Clinical Trial of OS2966 in Recurrent Glioblastoma

 


Click HERE to return to brain tumor news headlines.